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ure to progress, she had labour augmentation with oxytocin, and delivery was assisted by the use of midforceps. A healthy boy (3.023 kg) was delivered. The patient was discharged 1 day after delivery with blood pressure readings between 120/80 mm Hg and 135/85 mm Hg.
On postpartum day 5, the patient presented to the emergency department with a 1-day history of a gradualonset throbbing occipital headache that was associated with photophobia and 3 episodes of vomiting. Her blood pressure on presentation was 205/105 mm Hg. Her other vital signs were unremarkable. She was given prochlorperazine maleate (10 mg administered intravenously) as an antiemetic. On assessment by the emergency department physician, her blood pressure was 172/82 mm Hg, and she had moderate pitting edema in both feet. She had no meningism, and her neurologic examination showed only increased patellar deep tendon reflexes. At the end of the assessment (about 2 hours and 10 minutes after she arrived at the emergency department), she had a generalized seizure that lasted for 2 minutes. The seizure was terminated by diazepam (2 mg administered intravenously). Subsequently she was in a postictal state for 20 minutes. Five minutes after the seizure, her blood pressure was 130/70 mm Hg.
Initial laboratory investigations showed mild leukocytosis (leukocyte count 14.8 × 10 9 ) and mild anemia with a
• Late postpartum eclampsia is eclampsia that develops more than 2 days after delivery.
• Maternal blood pressure should be monitored at the time of peak postpartum blood pressure (days 3-6 after delivery) to detect eclampsia before symptoms develop.
• Late postpartum eclampsia can occur up to 23 days after delivery.
• A history of diagnosed pre-eclampsia is not essential for the development (or diagnosis) of late postpartum eclampsia.
• Severe headache is the most common presenting symptom, followed by edema, visual changes and epigastric pain.
• Brisk deep tendon reflexes and hypertension are the most common clinical signs.
• An eclampsia-induced seizure can occur in a patient with normal blood pressure.
• Magnesium sulfate is the best available treatment for eclampsia-induced seizure. . The results of a computed tomography (CT) scan of her head performed without contrast and subsequent lumbar puncture were normal. Two hours after the initial seizure, the patient reported having no headache, and her mental status was clear. Her blood pressure was 104/49 mm Hg. The results of a neurologic examination were unremarkable except for very exaggerated patellar deep tendon reflexes. Minutes later, the patient had a second generalized seizure that was terminated with lorazepam (2 mg administered intravenously). An intravenous magnesium sulfate drip was started as per protocol (4 g loading dose followed by 2 g per hour). The patient was transferred to the intensive care unit, where she continued to receive intravenous magnesium sulfate. She was also given intravenous phenytoin, labetalol (200 mg orally twice a day) and hydralazine (10 mg intravenously every 6 hours and hourly as required for systolic blood pressure over 160 mm Hg or diastolic blood pressure over 110 mm Hg). In the intensive care unit, her highest blood pressure was 187/102 mm Hg, which was normalized with antihypertensive therapy.
On the day after admission, magnetic resonance imaging (MRI) and magnetic resonance venography showed bilateral, marked subcortical white signal changes predominantly in the occipital lobes. There were small patchy areas of involvement in the frontal lobes and the posterior temporal lobes ( Figure 1 ). These changes were in keeping with changes seen in eclampsia.
Two days later, she was discharged home. She was prescribed labetolol (200 mg, taken orally twice a day). An MRI scan taken 3 months showed normal findings.
Our patient had late postpartum seizure and hypertension that occurred without true pre-existing pre-eclampsia. Eclampsia is a serious complication of pregnancy and is characterized by tonic-clonic seizure. Usually eclampsia occurs after the onset of pre-eclampsia, although sometimes no pre-eclamptic symptoms are observed. Pre-eclampsia is defined as hypertension (pre-existing or gestational onset after 20 weeks' gestation) with a diastolic blood pressure of 90 mm Hg or greater at 2 or more visits using the same arm and either proteinuria (0.3 g/d in a 24-hour urine collection or 30 mg/mmol creatinine in a random urine sample) or 1 or more of the adverse conditions listed in Box 1. Late postpartum eclampsia is eclampsia that develops more than 2 days after delivery. 1, 2 Eclampsia affects less than 0.2% of pregnancies, and it accounts for 1.5 pregnancy-related maternal deaths per 100 000 live births. [3] [4] [5] Eclampsia is the second leading cause of maternal death (19.6%) in the United States, after pulmonary embolism. 5, 6 Between 14% and 33% of cases of eclampsia occur after delivery. 7 Late postpartum eclampsia affects between 4% and 26% of patients with eclampsia and between 28% and 79% of patients with postpartum eclampsia. [7] [8] [9] [10] Despite a decline in the overall incidence of eclampsia because of the early diagnosis and treatment of pre-eclampsia, the incidence of late postpartum eclampsia remained unchanged between 1931 and 1991. 11 Thus, the relative incidence of late postpartum eclampsia is increasing. 4 The cause of pre-eclampsia and its progression to eclampsia or late postpartum eclampsia is unknown. The widely ac- cepted theory is based on a mismatch between uteroplacental supply and fetal demand that results in endothelial cell injury and widespread vasospasm that culminates with clinical symptoms due to multiorgan ischemia. 7, 9, 11, 12 There are several recognizable factors that increase the risk of eclampsia (Box 2).
Clinical characteristics
The clinical characteristics of pre-eclampsia and eclampsia are presented in Box 3. Hypertension may develop for the first time after delivery, with a peak blood pressure 3-6 days after delivery. This corresponds with the mobilization of extracellular fluid accumulated during pregnancy. 12 Thus, blood pressure measurement during the first week after delivery is key, even for women with previously normal blood pressure.
One-third of women with late postpartum eclampsia have no prior history of hypertension, proteinuria or edema. 3, 10 Two retrospective reviews showed that, for 44%-79% of patients with late postpartum eclampsia, pre-eclampsia was not diagnosed before the onset of seizures. 7, 9 Pulmonary edema, hepatic failure, hemolysis, elevated liver enzyme levels, low platelet count and disseminated intravascular coagulation are several well-recognized complications of eclampsia. 8 Abnormalities may be present in the patient's complete blood count, blood film, electrolytes, international normalized ratio and partial thromboplastin time. There may also be abnormalities in the patient's levels of aspartate transaminase, alanine transaminase, lactate dehydrogenase, bilirubin, albumin, creatinine, urea, uric acid, glucose, fibrinogen and fibrin degradation products. 12 Diagnostic imaging is not essential for diagnosing eclampsia. However, imaging can support the diagnosis by showing edema in the posterior regions of the cerebral hemispheres on an otherwise normal CT or MRI scan. 8, 13, 14 
Management
Early recognition of the signs of eclampsia (Box 3) in women who are pregnant or who have recently given birth may allow for the early use of anticonvulsant drugs, such as magnesium sulfate. The differential diagnosis of a postpartum seizure is shown in Box 4.
Although delivery of the newborn usually corrects the signs and symptoms of pre-eclampsia and eclampsia, this does not occur in the case of late postpartum eclampsia.
Several studies have examined therapeutic protocols for the management of eclampsia. However, these protocols have not been evaluated in late postpartum eclampsia. 15 Because late postpartum eclampsia is considered a subtype of eclampsia, the same therapeutic approaches can be used. Intravenous magnesium sulfate therapy (bolus of 2-4 g delivered over 10-30 minutes, followed by an infusion of 1-2 g per hour for 24-48 hours) has been found to be superior to other anticonvulsive therapies. 8, 12, 15 However, excessive levels of magnesium sulfate can lead to hypotension, loss of reflexes and respiratory arrest.
One may question whether the use of prochlorperazine may have helped to precipitate our patient's seizure. There is a reported low incidence of seizures being precipitated by the use of dopamine antagonists. We feel that the use of prochlorperazine was unlikely to have had a role in our patient's seizure. She had clear clinical findings of pre-eclampsia (headache, severe hypertension and increased deep tendon reflexes). The results of an MRI were also consistent with eclampsia.
Several agents can be used to treat hypertension in patients with pre-eclampsia, eclampsia and postpartum hypertension (Box 5). Diuretics should be avoided, especially in combination with other antihypertensive agents, except in cases of lifethreatening fluid overload. 8, 12 This is because, although one might expect patients with eclampsia to have increased total body fluids, they actually have a depletion of intravascular volume, and the use of diuretics can precipitate severe hypotension. The guidelines of the Society of Obstetricians and Gynaecologists of Canada state that, on average, longer durations Nonsteroidal anti-inflammatory drugs should not be given after delivery if the patient's hypertension is difficult to control. Gestational hypertension usually resolves within 6 weeks after delivery; however, women with severe preeclampsia may have hypertension for several months after delivery.
With the recent trend of discharging new mothers soon after delivery (often within 1 day), patients with eclampsia may present to primary care physicians and emergency departments with early signs and symptoms of eclampsia. The early recognition of the signs and symptoms of postpartum eclampsia may lead to early treatment and fewer complications.
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